title: [Monitoring the side effects of cancer chemotherapy with patients--participation of patients in cancer therapy and sharing patient information].
abstract: The purpose of this study was to assess patient participation in cancer therapy and the sharing of patient information among the medical care team (physicians, nurses, pharmacists, and especially patients). We monitored the side effects of cancer chemotherapy with patients, and developed two support tools: One scored the points of subjective symptoms (fatigue, anorexia, nausea, etc) by patients, and the other recorded objective symptoms (clinical examination data) by pharmacists. It is most important that they attend each patient at their bedside. At this time, the trial was evaluated by questionnaire survey by inpatients receiving cancer chemotherapy (n=15). As a result, all patients (15/15) responded that this trial was necessary. This trial addressed the following: 1) increased communication between patients and medical staff concerning side effects (14/15), 2) increased interest in side effects (10/15), 3) when a patient tells medical staff about side effects, they act on it (10/15). None of the patients felt inconvenienced by scoring every day (0/15), or anxiety about side effects (0/15). Furthermore, all patients (15/15) responded that "participation of pharmacists in cancer chemotherapy" was necessary. This trial revealed no problems and suggested that patients related to the center of medical care. We should be careful in interpreting results of this small sized trial; however, the following conclusions should be reached: 1) introduction of monitoring side effects of cancer chemotherapy with patients, 2) develop communication among the medical care team.
authors.affiliation: Department of Pharmacy, Kagawa University Hospital, Japan. khitochi@med.kagawa-u.ac.jp
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Kawazoe
authors.forename: Tomomi
authors.initials: T
authors.lastname: Kubo
authors.forename: Naomi
authors.initials: N
authors.lastname: Iihara
authors.forename: Chiaki
authors.initials: C
authors.lastname: Doi
authors.forename: Makiko
authors.initials: M
authors.lastname: Okujyoh
authors.forename: Noriyasu
authors.initials: N
authors.lastname: Fukuoka
authors.forename: Satoshi
authors.initials: S
authors.lastname: Fujimoto
authors.forename: Nobuhiro
authors.initials: N
authors.lastname: Kanaji
authors.forename: Shuji
authors.initials: S
authors.lastname: Bandoh
authors.forename: Toshihiko
authors.initials: T
authors.lastname: Ishida
authors.forename: Yoshiharu
authors.initials: Y
authors.lastname: Takiguchi
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Houchi
mesh_terms: D016907:Adverse Drug Reaction Reporting Systems; D000970:Antineoplastic Agents / Q000009:adverse effects*; D016903:Drug Monitoring / Q000379:methods*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000523:psychology; D010348:Patient Care Team; D010358:Patient Participation; D010595:Pharmacists; D024382:Professional Role; D011795:Surveys and Questionnaires
chemical_list: D000970:Antineoplastic Agents